Affiris Ag

Intercell Ag

Affiris Forschungs-und Entwicklungs Gmbh

Valneva Austria Gmbh

Advantage Therapeutics, Inc.

Accanis Biotech F&e Gmbh & Co Kg

Frank Mattner

Walter G Schmidt

Michael Buschle

Achim Schneeberger

Markus Mandler

Wolfgang Zauner

Guenther Staffler

Jörg Fritz

Eszter Nagy

Karen Lingnau

Alena Egyed

Andreas Mairhofer

Arne Von Bonin

Christine Landlinger

Andrea Dolischka

Christian Gieffers

Sylvia Brunner

Christoph Klade

Oresta Vytvytska

Petra Lührs

Helen Kirlappos

Sandra Zinke

Alexander Otava

Jack Melling

Julia-Kristina Fleitmann

Oleksandr Otava

Barbara Wittmann

Petra Luehrs

Günther Staffler

Martina Lutterova

Jorg Fritz

Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.

Treatment of Alzheimer's Disease (AD) with an aluminum salt

The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with &#x3b2;-amyloid deposition, preferably AD.

Treatment and prevention of alzheimer's disease (AD)

Treatment of alzheimer'S disease (AD) with an aluminum salt

The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.

Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide

The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X)KDXQLGX(SEQ ID No. 99), wherein Xis an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, Xis an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. Xis (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, Xis VVASQLR (SEQ ID No. 101) or an N-terminal truncated fragment thereof consisting of 1 to 6 amino acid residues, Xis an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glutamic acid, histidine, arginine, isoleucine, lysine, methionine, serine and threonine, m is 0 or 1, and n is 0 or 1, wherein said at least one peptide is coupled or fused to a carrier comprising at least one T-cell epitope.

Method of inhibiting C5a

Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A&#x3b2;-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: &#x2014;contacting the sample with A&#x3b2;-aggregates or with particles having A&#x3b2;-aggregate like surfaces and allowing the A&#x3b2;-specific antibodies to bind to the A&#x3b2;-aggregates, and &#x2014;detecting the A&#x3b2;-specific antibodies bound to the A&#x3b2;-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A&#x3b2;-specific antibodies detected is compared with the amount in a sample of known AD status.

Method for diagnosing alzheimer's disease (AD)

The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRANISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).

Methods for inhibiting C5a with C5a peptides coupled or fused to a carrier protein

Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence 

Vaccine

The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R&#x2014;XZXZXZX&#x2014;R, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and Rand Rare selected independently one from the other from the group consisting of &#x2014;H, &#x2014;NH, &#x2014;COCH, &#x2014;COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X&#x2014;Rmay also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.

Vaccine composition comprising an antigen and a peptide having adjuvant properties

The present invention relates to a method for treating atherosclerosis and/or atherosclerosis sequelae with a compound that includes

Treatment of atherosclerosis with cholesterol ester transport protein mimotopes

The present invention relates to the use of mimotopes in the treatment of diseases associated with &#x3b2;-amyloid formation and/or aggregation (&#x3b2;-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to A&#x3b2;1-40/42, A&#x3b2;pE3-40/42, A&#x3b2;3-40/42 and A&#x3b2;11-40/42.

Compounds for treating beta-amyloidoses

The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R&#x2014;XZXZXZX&#x2014;R, whereby

The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.

Pharmaceutical composition comprising an antigen

The invention relates to the use of a compound comprising the following amino acid sequence XXXXXXX, wherein X1 is an amino acid, except of C, Xis an amino acid, except of C, Xis an amino acid, except of C, Xis an amino acid, except of C, Xis an amino acid, except of C, Xis not present or any amino acid, Xis not present or any amino acid, and wherein XXXXXXis not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal A&#x3b2;42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal A&#x3b2;42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.

Method for preventing and treating Alzheimer's disease

The invention relates to a method for treating Alzheimer's disease by inducing sequestration of amyloid &#x3b2; into a plasma with a A&#x3b2;-mimotope peptide, and treatment with an apheresis device such that a fixed carrier can come into contact with the blood or plasma flow and includes a receptor that binds to an amyloid-&#x3b2; precursor-protein (APP), the APP being removed from the blood with the apheresis device.

Growing community of inventors

Vienna, Austria

Frank Mattner